We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current MPSYF market cap is 2.5B. The company's latest EPS is EUR and P/E is N/A.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 71.76M | 327.7M | 179.61M | 278.27M | 238.28M |
| Operating Income | -107.74M | 18.29M | -508.22M | -225.03M | -259.68M |
| Net Income | -103.01M | 97.89M | -514.46M | -151.06M | -189.73M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 496.44M | 1.66B | 2.56B | 2.4B | 2.03B |
| Total Liabilities | 101.74M | 1.04B | 2.31B | 2.24B | 1.98B |
| Total Equity | 394.7M | 621.32M | 244.88M | 157.41M | 49.05M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -80.14M | 35.27M | -481.45M | -366.71M | -295.84M |
| Investing | 78.55M | -879.62M | -831.01M | 345M | 15.37M |
| Financing | 353k | 907.19M | 1.32B | 311.42M | 43M |
| Market Cap | 2.5B |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 34.16M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 161.12% |
| 52 Week High | 73.27 |
| 52 Week Low | 20.15 |
| Spread (Intraday) | 0 (0%) |
| Company Name | MorphoSys AG (PK) |
| Address |
lena-christ-str. 48 munich 82152 |
| Website | https://www.morphosys.com |
| Industry | pharmaceutical biolog/vaccines (H23) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
